TheALKtranslocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TheALKtranslocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre
Authors
Keywords
-
Journal
HISTOPATHOLOGY
Volume 62, Issue 4, Pages 609-616
Publisher
Wiley
Online
2012-10-03
DOI
10.1111/his.12037
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incorporation of Crizotinib into the NCCN Guidelines
- (2017) Gregory J. Riely et al. Journal of the National Comprehensive Cancer Network
- EML4-ALK Fusion Lung Cancer: A Rare Acquired Event
- (2015) Sven Perner et al. NEOPLASIA
- The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
- (2012) A J Atherly et al. BRITISH JOURNAL OF CANCER
- Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement,ALKsignal copy number, and response to crizotinib therapy inALKfluorescence in situ hybridization-positive nonsmall cell lung cancer
- (2012) D. Ross Camidge et al. CANCER
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- (2012) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
- (2012) N. Rekhtman et al. CLINICAL CANCER RESEARCH
- ALK-Rearranged Lung Cancer: Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma
- (2012) Jamie E. Chaft et al. Journal of Thoracic Oncology
- Biology-driven medicine: tissue matters
- (2012) The Lancet Oncology LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
- (2012) Heae Surng Park et al. LUNG CANCER
- ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma
- (2012) Sanjay Popat et al. LUNG CANCER
- Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene
- (2012) Takayuki Fukui et al. LUNG CANCER
- Treating ALK-positive lung cancer—early successes and future challenges
- (2012) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
- (2011) Akihiko Yoshida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Identification of Genes Upregulated in ALK-Positive and EGFR/KRAS/ALK-Negative Lung Adenocarcinomas
- (2011) H. Okayama et al. CANCER RESEARCH
- Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race
- (2011) Javier de Castro-Carpeño et al. Clinical & Translational Oncology
- Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method
- (2011) Elena García-García et al. HISTOPATHOLOGY
- ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers
- (2011) Samuel J. Klempner et al. Journal of Thoracic Oncology
- Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH
- (2011) Eunhee S. Yi et al. Journal of Thoracic Oncology
- MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
- (2011) Junko Tanizaki et al. Journal of Thoracic Oncology
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study
- (2011) Anne McLeer-Florin et al. Journal of Thoracic Oncology
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers
- (2011) Pierre-Alexandre Just et al. LUNG CANCER
- Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer
- (2011) Jin Ho Paik et al. LUNG CANCER
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
- (2010) M. Mino-Kenudson et al. CLINICAL CANCER RESEARCH
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma
- (2010) R. Jokoji et al. JOURNAL OF CLINICAL PATHOLOGY
- A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations
- (2010) Bárbara Angulo et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
- (2010) Marta Salido et al. Journal of Thoracic Oncology
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
- (2010) Esther Conde et al. PLoS One
- EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
- (2009) Maria Paola Martelli et al. AMERICAN JOURNAL OF PATHOLOGY
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
- (2009) S. J. Rodig et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search